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Abstract: ErbB-2 is one of Tour cell surface growth factor receptors involved in transmis-
sion o f signals controlling normal cell growth and differentiation. A range o f growth 
factors serve as ligands, but none is specific for the ErbB-2 receptor. Ligand binding to 
ErbB-1, ErbB-3 and ErbB-4 induces rapid receptor dimerization, with a marked preference 
for ErbB-2 as a dimer partner. When ErbB-2 is overexpressed multiple ErbB-2 hetero-
dimers are formed and cell signalling is stronger, resulting in enhanced responsiveness to  
growth factors and malignant growth. This explains why ErbB-2 overexpression is an 
indicator o f poor prognosis in colorectal cancers and may be predictive of response to 
treatment. ErbB-2 is a highly specific and promising target for new colon cancer treat-
ments.
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1. Introduction
The erbB-2 (neu, HER-2) oncogene is located on chromosome 17ql 1—q22 
and encodes a 185 kDa transmembrane glycoprotein which has a structure 
consistent with a growth factor receptor, due to its similarity to the human 
epidermal growth factor receptor (EGFR) (R u b in  and Y a r d e n  2001). The 
neu gene was originally identified in rat neuroectodermal tumours and later 
its close human relative was isolated (Shih et al. 1981).
The ErbB-2 receptor has an important role in normal cell growth and 
differentiation. However, amplification of the erbB-2 gene leads to overex-
pression of the receptor, which is linked to the development of many types
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of human cancers including breast, ovarian and those of the gastrointes-
tinal tract ( H y n e s  and S t e r n  1994; B r y ś  et al. 2001; R u b in  and Y a r -  
d e n  2 0 0 1 ).
Adenocarcinomas of the colon and rectum are one of the major 
cause of morbidity and mortality for men and women. The pathologic 
stage of the tumor following surgical resection has long served as the 
cornerstone for predicting outcome for colorectal cancer ( g e l b  and 
SCHROCK 1997; ROSS et al. 2001). Thus, considerable recent interest 
has developed for the evaluation of new prognostic and predictive ma-
rkers that could be applied to early stage lesions (indicating their pro-
pensity for relapse) and the selection of these patients with relatively 
superficially invasive tumors to receive adjuvant therapy (R O SS et al. 
2001).
In colorectal cancer ErbB-2 overexpression appears to be a significant 
adverse outcome indicator as judged by the current published literature. 
Either ErbB-2 protein overexpression or gene amplification is associated 
with a significant percentage of gastrointestinal adenocarcinomas. However, 
there are data suggesting that ErbB-2 overexpression or amplification is 
a significant prognostic factor for gastric and colorectal carcinomas. If this 
prognostic significance is confirmed, strategies designed to employ the 
marker in therapy selection appear to be warranted.
2. ErbB Family of Rectors and its Ligands
The ErbB family comprises four distinct receptors: EGFR/ErbB-1, 
ErbB-2/HER-2/neu, ErbB-3/HER-3, ErbB-4/HER-4. In general these cell 
surface receptors are composed of an extracellular ligand-binding domain, 
transmebrane part and a cytoplasmic region with tyrosine kinase activity 
(Fig. 1) ( U l l r i c h  and S c h l e s s i n g e r  1990; K j le in  et al. 2001; T r o j a n e k  
2002). This structure enables signals to be transmitted across the plasma 
membrane where they activate gene expression and ultimately induce 
cellular responses such as proliferation. The signal-transducing tyrosine 
kinase activity of the ErbB receptors is inactive when the receptors are in 
isolation (Ya r d e n  2001).
ErbB receptors are activated by a number of ligands, referred to as 
EGF- related peptide growth factors. These include epidermal growth factor 
(EGF), amphiregulin (AR) and transforming growth factor a (TGFa) which 
bind specifically to ErbB-1, betacellulin (BTC), heparin-binding EGF 
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Fig. 1. Structure of the ErbB family receptors and bivalence o f EGF-like ligands. The model 
refers to neuregulin-1 and transforming growth factor a and is based on results described in
T z a h a r  e t  a l. (1997)
bind both ErbB-1 and ErbB-4, and at least four subfamilies of neuregulins 
(NRG14). NRG1 and NRG2 both bind ErbB-3 and ErbB-4, whereas 
NRG3 and NRG4 bind ErbB^ł (PELES and YARDEN 1993; KlRSCHBAUM 
and Ya r d e n  2000; O l a y i o y e  et al. 2000).
Despite the large number of ligands so far identified for ErbB-1, ErbB-3 
and ErbB-4, as well as intensive efforts, no direct ligand for ErbB-2 has 
yet been discovered. ErbB-2 appears to act as a ligand less receptor. It 
was stated that ligand binding to ErbB-1 (EGF), ErbB-3 (NRG1) or 
ErbB-4 (NRG1, BTC) induces the formation of receptor homodimers and 
ErbB-2 containing heterodimers. In fact, ErbB-2 is the preferred hetero- 
dimerization partner for all other ErbB family members and plays a role 
in the potentiation of ErbB receptor signalling (Fig. 2) (GRAUS-PORTA et 
al. 1995; T z a h a r  et al. 1996, 1997; O l a y i o y e  et al. 2000; Ya r d e n  2001). 
From ten possible combinations, those heterodimers that contain ErbB-2 
are more stable and their signalling is more potent than that of other 
receptor combinations (Tz a h a r  et al. 1996; Pe n u e l  et al. 2001).
Multiple ligands differ in their expression patterns and in the ability to 
form specific homo- and heterodimeric receptor complexes. Due to the 
latest hypothesis, this latter difference is caused by the existence of two 
receptor binding sites on each ligand. The model refers to neuregulin-1 
and is based on results described by TZAHAR et al. (1997). Neuregulin-1 
seems to be a bivalent molecule with two binding sites for ErbB receptors:
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Fig. 2. Signalling by ErbB homodimers in comparison with ErbB-2-containing heterodimers. 
Binding of a ligand (EGF or NRG) to the extracellular domain of ErbB-1 or ErbB-3 (note 
inactive kinase marked by a cross) induces homodimer formation. When ErbB-2 is overexpressed, 
heterodimers form preferentially. Unlike homodimers, which are either inactive (ErbB-3 
homodimers) or signal only weakly, ErbB-2-containing heterodimers have attributes that 
prolong and enhance downstream signalling (white box) and their outputs (grey box)
a high affinity/narrow specificity site (N-terminal) and a low affinity with 
broad specificity site (С-terminal). By the high affinity site ligand binds to 
its specific receptor (Fig. 1). Once the low affinity site is effectively 
‘immobilized’ at the plasma membrane, its operational affinity to potential 
partners of the dimer is increased. Importantly, the receptor that preferentaially 
binds to the immobilized low affinity arm of the ligand is ErbB-2. As 
a result of this heterodimerization, the ErbB-2 receptor is able to participate 
in signal transduction in the absence of a specific ligand. This preferential 
binding with ErbB-2 is also enhanced by the overexpression of ErbB-2 in 
human cancer cells (TZAHAR et al. 1997).
Heterodimer formation is especially important between ErbB-2 and 
ErbB-3, not only because a high-affinity ligand-binding site is formed but 
also because ErbB-2 provides an active tyrosine kinase (EC 2.7.1.112) for 
the catalytically impaired ErbB-3 (G u y  et al. 1994). Homodimerization of 
ErbB-3 or ErbB-4 results in the formation of a low-affinity neuregulin 
binding site, whereas heterodimerization between ErbB-2 and either ErbB-3 
or ErbB-4 is sufficient for the formation of a high-affinity binding site 
(F i t z p a t r i c k  et al. 1998; Pa n u e l  et al. 2001).
3. Mechanism of action of ErbB family receptors
Ligand-induced receptor dimerization leads to transactivation and tyrosine 
autophosphorylation at site in the cytoplasmic carboxyl terminus. When 
phosphorylated, these residues can act as docking sites for SH2 (Src 
homology 2) or PTB (phosphotyrosine binding) domains containing proteins 
for activation of signalling pathways. The functions of a number of 
a substrates recruited by ErbB-2 receptor overlap, e.g. She (Src homology 
collagen homology) Grb-2 (growth factor receptor bound) and Chk (chec-
kpoint kinase) interacts with most if not all ErbB dimeric species. Other 
receptors interacts with selected substrates like phospholipase С у (PLCy), 
RasGAP (Ras GTPase activating protein) and Grb-7 (RICCI et al. 1995; 
D a n k o r t et al. 1997; Z rih an -L ich t et al. 1998; O lay ioy e et al. 2000, 
2001). All ErbB family members activate the МАРК (mitogen-activated 
protein kinase) pathway. Activation of Ras МАРК pathway is regulated 
by association of Grb-2 or She and phosphorylated ErbB-2. Activation of 
phosphatidylinositol-3 kinase is regulated by its association with YXXM 
motifs in the carboxy terminus of ErbB-3 and Cbl (Casitas B-lineage 
lymphoma) that specifically associates with EGFR, all of which contribute 
to cell growth and survival. The kinetics and potency of MAP kinase 
activation exhibit significant dependency on the identity of receptor dimers. 
Heterodimers are more sustained activators than homodimers, and hetero-
dimers containing ErbB-2 are especially potent in this regard ( T z a h a r  and 
Y ard en  1998; P en u e l et al. 2001). ErbB-2-containing heterodimers display 
increased ligand affinity due to a deacelerated off rate that can be correlated 
with prolonged activation of downstream signalling pathways (G RO US-PO RTA  
et al. 1995).
Heterodimers containing ErbB-2 remain at the cell surface for a lon-
ger period of time, undergoing endocytosis at lower rate than homo- 
dimers do. Furthermore, once the activated complex is internalized ErbB- 
2/ErbB-l heterodimers are targeted for recycling, while ErbB-1 homo-
dimers are destined for degradation. The recycling pathway returns recep-
tors to the cell surface, ready for another cycle of activation and au-
gments growth-factor signalling ( L e n f e r i n k  et al. 1998; P e n u e l  et al. 
2001; Y a r d e n  2001).
Furthermore, biological responses such as proliferation, morphological 
differentiation and migration/ invasion are enhanced in cells expressing 
ErbB-2 ( G r o u s - P o r t a  et al. 1995; K a r u n a g a r a n  et al. 1996; S p e n c e r  
et al. 2000; O l a y i o y e  et al. 2001).
ErbB heterodimerization is a means not only for signal amplification 
but also for signal diversification. The subset of SH2- and PTB-binding
signalling molecules recruited to an activated receptor are defined by the 
pattern of phosphorylated tyrosine residues in the C-terminus of the 
receptor. Based on the finding that the Cbl protein coupled only to EGF- 
but not to NRG-activated ErbB-1 it is speculated that signal diversifica-
tion arises at one level by differential transphosphorylation of a given 
receptor in distinct ErbB dimers (G r o u s -Po r t a  et al. 1995; O l a y i o y e  et 
al. 2000).
Signalling diversity emanating from the ErbB family is generated by the 
repertoire of ErbB ligands and the combinatorial properties of induced 
receptor dimers. With the exception of EGF, which is found in many fluids, 
ErbB ligands generally act over short distances as autocrine or paracrine 
growth factors. The availability of a specific ligand is, therefore, one way 
to control its signalling ability. In this respect, ErbB ligands demonstrate 
distinct expression patterns that are organ- and developmental stage-specific 
(O l a y i o y e  et al. 2000).
4. ErbB-2 receptor and cancer
ErbB-2 is a protein expressed in a variety of tissues of epithelial origin 
and it plays a fundamental role in cellular proliferation and differentiation 
during fetal development. In adults, the erbB-2 gene is present as a single 
copy and protein overexpression is seen in various cancers including breast, 
ovarian, colon, uterine, gastric, prostate and adenocarcinoma of the lung 
(Be r n h a r d  et al. 2002).
ErbB-2 overexpression triggers ligand-independent activation of the 
kinase domain, apparently as a result of spontaneous dimmer formation. 
Homodimerization of ErbB-2 can be achieved by mutating a single amino 
acid residue in the transmembrane domain, leading to constitutive dimerization 
and activation of this receptor (Ba r g m a n n  et al. 1986; Ol a y i o y e  et al. 
1998; Pe n u e l  et al. 2001). Although ErbB-2 homodimers alone may 
contribute to malignancy, a number of observations suggest that ErbB-2 
does indeed cooperate with other ErbB receptors during tumor development 
(Ha r a r i  and Ya r d e n  2000; Ol a y i o y e  et al. 2000). Many human tumors 
that contain ErbB-2 also exhibit autocrine stimulation of ErbB-1 via 
expression of one of its numerous ligands (SALOMON et al. 1995; DlGlOVAN- 
NA et al. 1998). The ability of ErbB-2 to potentate ErbB-1 signalling would 
provide tumor cells with a more potent growth stimulus and could lead to 
the activation of additional intracellular pathways. Such cooperation would 
contribute to the maintenance of increased proliferation rates associated 
with tumor development.
ErbB-2 and ErbB-4 are also coexpressed in more than 50% of child-
hood medulloblastomas, and the ErbB-4 ligand NRG1 is found in a sig-
nificant proportion of the same tumors. Coexpression of ErbB-2 with 
ErbB-4 can enhance the effects of autocrine or paracrine NRG1 signalling 
( O l a y i o y e  et al. 2000). Another important observation pertaining to 
ErbB heterodimer collaboration during tumor development is that expres-
sion of ErbB-3 is seen in many of the same tumor types that overexpress 
ErbB-2, including breast, bladder and melanoma ( G i l b e r t s o n  et al.
1997).
ErbB-2 and ErbB-3 function together to stimulate mitogenic signalling 
networks. This in turn contributes to uncontrolled tumor cell proliferation 
by a mechanism involving deregulation of the G l-S  transition through 
modulation of the activation status of the essential G l-S  regulator cyclin 
E-dependent kinase 2 ( N e v e  et al. 2000; O l a y i o y e  et al. 2000).
The relatively low, normal expression o f ErbB-2 level is enhanced in 
several types of carcinomas. For example 25 -r- 35% of ovarian carcinomas 
show overexpression o f ErbB-2 and survival o f patients with ErbB-2  
overexpression is significantly shorter than survival o f non-overexpressors 
(TZAHAR and Y ar d e n  1998). Lung cancer is another example. Unlike 
squamous lung carcinomas, where the significance o f overexpression is still 
un settled, 30 h- 35% o f lung adenocarcinomas display overexpression, 
which correlates with shorter patient survival time (K ern  et al. 1990; 
T a teish i 1991; LOPEZ-GUERRERO et al. 1999). Overexpression of ErbB-2 
due to gene amplification occurs in about 20 h- 30% of breast tumors but 
particularly (~ 9 0% ) in comedo forms of ductal carcinoma in situ (DCIS), 
a malignant ductal carcinoma that has not progressed beyond the basement 
membrane barrier (BAR N ES et al. 1992). Even after progression to invasive 
disease, a correlation with the DCIS subtype and ErbB2 overexpression is 
maintained. Importantly, high ErbB-2 level predicts lower disease-free and 
overall survival in both lymph node negative and particularly in lymph 
node positive tumors, indicating a functional role o f ErbB-2 in breast 
cancer (B arn es  et al. 1992; Liu et al. 1992; T z a h a r  and Y ar d e n  1998; 
D o w s e tt  M. 2000; H a r a r i  and Y ar d e n  2000).
Other types of carcinomas that show variable overexpresion are those 
of the kidney ( S e l l i  et al. 1997), bladder ( I m a i et al. 1995; R a j k u m a r  
et al. 1996; T A N N  APFEL et al. 1996), salivary gland ( S k a l o v a  et al. 2001), 
prostate ( A g u s  et al. 2000; S anC H E Z  et al. 2002) and the pancreas ( S a t o h  
et al. 1993; K O K A  et al. 2002). However, the prognostic significance of 
overexpression in these tumors is not as clear as in breast, ovarian and 
lung cancers.
The other reason of ErbB-2 changes observed in cancers seems to be 
connected with polymorphism at codons 654 and 655. E h s a n i  et al. (1993)
described a G-to-A polymorphism of the erbB-2 gene resulting in a varia-
tion from valine to isoleucine. The ile-ile, ile-val and val-val configura-
tions of codons 654 and 655 had frequencies of 0.782, 0.206 and 0.012, 
respectively. In a population-based case control study of the val655-to-ile 
polimorphism X lE  et al. (2000) found that the val allele was associated 
with an increased risk of breast cancer, particularly among younger 
woman.
Recently there has been a flurry of interest in the relationship between 
ErbB-2 and colon cancer. Normal colonic mucosa is negative for ErbB-2, 
but significant number of benign lesions and adenocarcinomas overexpressed 
this protein. Adenocarcinoma were significantly more positive than benign 
lesions. The ErbB-2 rate expression show significant correlation with the 
epithelial abnormality degree and clinical parameters including Dukes’ 
classification and relapse-free and postoperative survival period ( K a p i t a n o v i c  
et al. 1997). Colon cancer metastatic to liver or lymph nodes has higher 
levels of ErbB-2 (SAEKI et al. 1995).
In our studies erbB-2 mRNA expression was identified in 51.5% of 
colorectal carcinoma samples (17/33) and in 29% of normal colonic mucosa 
(6/21) (Fig. 3). Obtained results suggest also that the erbB-2 mRNA 
expression in colorectal cancer cells is correlated with the progression of 
the disease. The expression of the erbB-2 mRNA was found in 1/2 of colon 
cancer cases at stage A, in 2/11 at stage B, in 7/13 at stage С and 7/7 at 
stage D. However no differences were found in the level of erbB-2 mRNA 
expression and tumor size.
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Fig. 3. Representative RT-PCR analysis of the erbB-1 expression in colorectal cancer 
(lanes 1 -j- 5) and normal colonic mucosa (lanes б-т-8). Total RNA was isolated from  
normal and tumor specimens according to C h o m c z y n s k i  and S a c c h i  (1978), reverse 
transcribed using RNA PCR Kit ver.2.1 (Takara Shuzo Co., Ltd., Kyoto, Japan)  
and amplified with specific set оГ primers (5’- AACTGCACCCACTCCTGTGT-3’; 
5’-CAGGGATCCAGATGCCCTTG-3’) according to W o r t h y l a k e  et al. (1997). Amplification 
products were separated on the 1.5% TBE-agarose gel and visualized by ethidium bromide.
M, molecular weight markers; bp, base pairs
5. Conclusions
ErbB-2 is being investigated as a target for cancer therapy since is 
frequently overexpressed in human tumors and often confers a more 
aggressive clinical course. Its localization at the cell surface makes it an 
easy target to access. A wide range of therapeutic strategies targeting many 
tumors that overexpress ErbB-2 have been investigated, including tyrosine 
kinase inhibitors, antisense approaches designed to downregulate expression 
of the erbB-2 gene, and immunization to actively boost anti-ErbB-2 responses. 
In addition, selective targeting can be achieved using monoclonal antibodies 
directed against the extracellular domain of the ErbB-2 protein (De POTTER 
et al. 1995). Therefore, monoclonal antibodies are the potential greatest 
advance in the treatment of tumors overexpressiong ErbB-2. Elucidation of 
the role of ErbB-2 in cell growth should allow the mechanism of action 
of monoclonal antibodies to be determined and should help optimize 
treatment of aggressive ErbB-2-positive tumors.
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